Heart News and Research

RSS

Telit CC864-DUAL cellular module to connect next generation MCOT from CardioNet

Telit Wireless Solutions, a global leader in machine-to-machine (M2M) wireless technology, today announced its CC864-DUAL cellular module will connect the next generation Mobile Cardiac Outpatient Telemetry (MCOT) from CardioNet, Inc., a leading wireless medical technology company with a current focus on the diagnosis and monitoring of cardiac arrhythmias.

9 May 2012

Current anticoagulant therapy to prevent stroke might not be sufficient for older women with AF

In a study that examined use of the anticoagulant medication warfarin and risk of stroke following a diagnosis of atrial fibrillation in older patients, women, especially those 75 years or older, had a higher risk of stroke than men, regardless of their risk profile and use of warfarin, suggesting that current anticoagulant therapy to prevent stroke might not be sufficient for older women, according to a study in the May 9 issue of JAMA.

9 May 2012

Rutin may inhibit formation of blood clots

A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis.

9 May 2012

Medtronic’s Valiant Captivia Stent Graft now available in seven countries

Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. is expanding availability of the Valiant Captivia Thoracic Stent Graft System in several countries, including China, Japan and the United States.

From Medtronic 9 May 2012

Strategies for heart repair to be addressed at UH lecture

With the heart having limited ability to regenerate following injury, heart disease is the primary cause of morbidity and mortality in the developed world. Research impacting strategies for heart repair will be addressed during a lecture May 15 at the University of Houston (UH).

9 May 2012

Sorin launches FDA-approved PARADYM RF family of ICDs and CRT-D devices

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch of the PARADYM RF family of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices.

9 May 2012

Researchers discover location and effect of abnormal heart proteins

University of Guelph researchers have found the location and effect of abnormal heart proteins that can cause cardiac failure, a discovery that points to potential new ways to treat the most costly health problem in the world.

9 May 2012

UVA achieves two important milestones in VISIUS Surgical Theatre

IMRIS Inc. today reported on the preliminary successes that the University of Virginia (UVA) has achieved in their VISIUS Surgical Theatre. UVA clinicians have treated over 50 patients in their VISIUS Surgical Theatre since its opening, achieving two important milestones in the use of their new intraoperative imaging capabilities.

9 May 2012

Obese women more likely to have children with lower cognitive function

Women who are obese before they become pregnant are at higher risk of having children with lower cognitive function - as measured by math and reading tests taken between ages 5 to 7 years - than are mothers with a healthy prepregnancy weight, new research suggests.

9 May 2012

Call for cookery lessons in schools to reduce childhood obesity

Health professionals, charity leaders and celebrities, including Steven Gerrard and Jamie Oliver, are calling for cookery lessons to be introduced to schools for all children aged between 4 and 14 years old.

8 May 2012

Bioactive formulation for optimal eye health

Morinda Bioactives (formerly Tahitian Noni International) recently announced the release of seven new Fit Body Composition Supplements, one of which is Fit Eye. Fit Eye provides an exclusive formulation of highly effective bioactives derived from the most potent sources, including research-recommended levels of lutein, to support optimal eye health.

8 May 2012

'Good' cholesterol may not protect against coronary heart disease

A new study by Harvard School of Public Health (HSPH) researchers has found that a subclass of high-density lipoprotein (HDL) cholesterol, the so-called "good" cholesterol, may not protect against coronary heart disease (CHD) and in fact may be harmful.

8 May 2012

FDA approves St. Jude Medical's Assura family of implantable defibrillators

St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its Assura portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).

8 May 2012

LAA occlusion effectively reduces risk of stroke in patients with A-fib

Patients with atrial fibrillation (A-fib) who cannot take blood thinners now have an alternative to reduce their risk of stroke, which is five times more common in people with the rhythm disorder. The non-surgical procedure works by tying off the left atrial appendage (LAA), the source of most blood clots leading to stroke in patients with A-fib. Northwestern Medicine- heart rhythm specialists from the Bluhm Cardiovascular Institute were the first to perform this procedure in Illinois.

8 May 2012

Long-term exposure to roadways linked with increased risk of death in patients with heart attack

Living close to a major highway poses a significant risk to heart attack survivors, reinforcing the need to isolate housing developments from heavy traffic areas, a Beth Israel Deaconess Medical Center study concludes.

8 May 2012

Cheaper anti-blindness drug could save NHS £85 million annually

Avastin (bevacizumab), which is used to treat wet age-related macular degeneration – the most common cause of blindness among the elderly costs only £60 per injection. But despite trials showing it is no less effective, another drug, Lucentis, is the current official choice, even though it costs £700 per shot. Avastin is intended to treat bowel cancer, but research by the National Institute for Health Research has shown that it also works just as effectively and safely as Lucentis in treating Wet AMD.

8 May 2012

High rates of birth defects associated with an artificial reproductive technology: Study

A new study has shown that one of the most popular forms of IVF could double the risk of birth defects.

8 May 2012

Stereotaxis to highlight results from Epoch clinical study at HRS annual meeting

Stereotaxis, Inc. will highlight clinical results from the first 1,250 cases and the latest innovations for the Epoch platform, its new generation comprehensive solution for the electrophysiology (EP) laboratory, at the 33rd Annual Heart Rhythm Society (HRS) Scientific Sessions, May 9-12, 2012.

8 May 2012

CardioFocus’ HeartLight EAS to be highlighted at Heart Rhythm 2012

CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its technology will be highlighted both as part of the scientific sessions and during a private academic symposium at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, May 9-12 in Boston, MA.

8 May 2012

North Suburban Medical Center's Northeast ER opens today

North Suburban Medical Center's Northeast ER opens its doors today at the corner of Holly Street and 128th Avenue to receive emergency patients from the surrounding communities. The 10,000-foot, state-of- the-art emergency department will function just like a hospital-based ER, treating everything from minor injuries to more severe and life-threatening illnesses such as stroke or heart attack. Northeast ER is a true emergency facility, open 24-hours a day, 365 days a year.

8 May 2012